Jacobs Levy Equity Management
STSA

Jacobs Levy Equity Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Jacobs Levy Equity Management’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-78,535
Closed -$366K – 1109
2021
Q3 		$366K Sell
78,535
-3,207
-4% -$17K ﹤0.01% 907
2021
Q2 		$576K Sell
81,742
-92,654
-53% -$500K ﹤0.01% 839
2021
Q1 		$1.03M Sell
174,396
-21,255
-11% -$129K 0.01% 730
2020
Q4 		$902K Buy
+195,651
New +$843K 0.01% 749

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's STSA Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2021, closing a stake of 78,535 shares — an estimated $366K sold.

Jacobs Levy Equity Management first reported a position in STSA in Q4 2020 and held it in 4 quarters. The position peaked at $1.03M in Q1 2021. 35 funds tracked by Wall St. Rank hold STSA as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 78,535 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $366K.
  • Jacobs Levy Equity Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $1.03M in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.